“…Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are genetically modified GPCRs which allow researchers to control cellular activity via modulation of GPCR signaling with the application of selective ligands (Urban & Roth, 2015; Yu et al, 2020). These chemogenetic tools have been used to modulate the function of neurons and astrocytes in different brain regions (Armbruster et al, 2007; Alexander et al, 2009; Zhu et al, 2014; Koike et al, 2016; Adamsky et al, 2018; Jones et al, 2018; Durkee et al, 2019; Pati et al, 2019; Kol et al, 2020; Oguchi et al, 2021; Lei et al, 2022; Liu, S. et al, 2022). Using chemogenetic approach, astrocytic G i pathway activation in hippocampus has recently been shown to modulate cognitive functions (Jones et al, 2018; Kol et al, 2020; Liu, S. et al, 2022), although the mechanism is still not fully understood.…”